Grant Support

Current Grant Support

GlaxoSmithKline, “A long-term access programme for subjects with severe asthma who participated in a GSK-sponsored Mepolizumab clinical study” (2017-ongoing).  Jackson, PI

NIH/Office of the Director (UG3 OD023282), “Children’s Respiratory and Environmental Workgroup (CREW)” (2016-2023). Jackson, Co-Investigator

NIH/NIAID & Children’s Hospital of Boston (U01 AI126614), “Preventing Asthma in High Risk Kids (PARK)” (2016-2023). Jackson, Site PI

NIH/NHLBI & University of Arizona (U01 HL130045), “Oral Bacterial Extracts (ORBEX): Primary Prevention of Asthma and Wheezing in Children” (2016-2021). Jackson, Site PI

NIH/NIAID (UM1 AI114271). “Inner City Asthma Consortium 3 (ICAC3)” (2014-2021). Jackson, Co-Investigator & MUPPITS Protocol PI

GlaxoSmithKline, “An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma” (2015-2018). Jackson, PI


Completed Grant Support

NIH/NHLBI (P01 HL070831). “COAST – Rhinovirus Infections in Children and Adolescents” (2013-2019). Jackson, PI; Lemanske, Co-PI

Pharmaxis, “Mannitol Challenge in COAST” (2009-2019). Jackson, Co-Investigator

NIH/NHLBI & Pennsylvania State University (U10 HL098115). “AsthmaNet: STICS Protocol” (2013-2018). Jackson, Co-Investigator, STICS Protocol PI

NIH/NHLBI (U10 HL098090), “AsthmaNet: UW-Madison Clinical and Translational Research Center” (2013-2018). Jackson, Co-Investigator

NIH/NHLBI & Pennsylvania State University (U10 HL098115).  “Viral Determinations for AsthmaNet STICS Protocol (biome & main study)” (2014-2017).  Jackson, Subaward PI

NIH/NHLBI & Pennsylvania State University (U10 HL098115). “Viral Determinations for AsthmaNet INFANT-AVICA Protocol” (2013-2017). Jackson, Subaward PI

NIH/NHLBI & Pennsylvania State University (U10 HL098115). “Viral Determinations for AsthmaNet APRIL-OCELOT Protocol” (2011-2017). Jackson, Subaward PI

NIH/NIAID & University of Texas Health Science Center (U19 AI104317). “Mechanisms of Enhanced Enterovirus D68 Pathogenicity” (2014-2016). Jackson, Opportunity Fund PI

NIH/NIAID (U19 AI104317), “Mechanisms and Environmental Determinants of Rhinovirus Illness Severity” (2013-2016). Jackson, Project 1 Co-Investigator

NIH/NIAID & University of California-San Francisco (P01 AI089473). “Virus/Microbe Interactions and Asthma” under P01 AI089473: “Pets and the Infant Microbiome: Effect on Immune Maturation & Atopic Asthma” (2014-2015). Jackson, Subaward PI

NIH/NCRR, NIH/NCATS & UW Institute for Clinical & Translational Research (KL2 Career Development Scholar, KL2 RR025012 & KL2 TR000427). “Mechanisms linking immune dysregulation, allergy, viruses, and childhood asthma” (2010-2014). Jackson, KL2 Scholar

NIH/NCRR, NIH/NCATS & UW Institute for Clinical & Translational Research (UL1 RR025012 & UL1 TR000427), “Epithelial Cell Allergy-Virus Interactions in Asthma” (2011-2013). Jackson, Pilot Grant PI

American Academy of Allergy, Asthma & Immunology (AAAI, Fellow Career Development Award). “Cytokine dysregulation, virus infections, and asthma” (2009-2011). Jackson, PI